A restricted label can often be an impediment to reimbursement, but Sarepta Therapeutics, Inc. is hoping that the limits on Elevidys, its new gene therapy for Duchenne muscular dystrophy, will pressure payers to set reimbursement policies quickly so no eligible boys age out the treatment window before being able to get coverage.
Key Takeaways
-
Sarepta will push for reimbursement so boys don’t age out of restricted Elevidys label







